| DC10832 |
(E/Z)-4-hydroxy Tamoxifen
Featured
|
(E/Z)-4-hydroxy Tamoxifen is an active metabolite of tamoxifen that is formed by the action of cytochrome P450 2D6 in human liver. |
|
| DCE-016 |
Chenodeoxycholic acid |
>98%,Standard References |
|
| DCL-047 |
Sulforaphane |
>98%,Standard References |
|
| DC7575 |
10058-F4
Featured
|
10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression. |
|
| DC10075 |
10074-G5
Featured
|
10074-G5 is a c-Myc Max interaction inhibitor. |
|
| DCAPI1534 |
Alfacalcidol
Featured
|
1α-Hydroxyvitamin D3 is a form of vitamin D that helps the body absorb calcium from food. |
|
| DCAPI1409 |
Maxacalcitol |
22-Oxacalcitriol is a Vitamin D3 analog which is Non-calcemic as well as a VDR ligand. 22-Oxacalcitriol has been shown to decrease parathyroid hormone (PTH) mRNA expression in vitro. Additionally has been noted to exhibit similar effects to calcitriol in |
|
| DCAPI1508 |
25-OH-VD2 |
25-Hydroxyvitamin D2 is used in serum to measure the concentration of vitamin D produced by the skin. It is known that 25-Hydroxyvitamin D2 can be detected in human serum using high-performance liquid chromatography and ultraviolet detection. Vitamin D2, |
|
| DC9044 |
2-Methoxyestradiol
Featured
|
2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 μM for the inhibition of BPAEC migration. |
|
| DC10415 |
4E2RCat
Featured
|
4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM. |
|
| DC7349 |
4EGI-1
Featured
|
4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM. |
|
| DC10037 |
4μ8C
Featured
|
4μ8C is a potent and selective IRE1 Rnase inhibitor with IC50 of 76 nM. |
|
| DC10187 |
666-15
Featured
|
666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM. |
|
| DC11530 |
Tapinarof (Benvitimod; GSK2894512)
Featured
|
Tapinarof (WBI-1001) is a natural aryl hydrocarbon receptor (AhR) agonist with an EC50 of 13 nM. Tapinarof resolves skin inflammation in mice. |
|
| DC11658 |
Diptoindonesin G
Featured
|
Dip G is a natural compound, novel chemical probe reciprocally stabilizes ERβ and destabilizes ERα in breast cancer cells; targets CHIP ubiquitin E3 ligase to modulate ER protein stability, enhances the transcription and anti-proliferative activities of ERβ, while attenuating the transcription and proliferative effects of ERα; the first small molecule that can restore the balance of ERα and ERβ. |
|
| DC11751 |
UHC1 |
A novel potent, non-agonist PPARγ ligand that blocks CDK5-mediated PPARγ phosphorylation, without the classical agonism. |
|
| DC11750 |
SR-1664
Featured
|
SR-1664 is a novel potent, non-agonist PPARγ ligand that blocks the Cdk5-mediated phosphorylation in vitro (IC50=80 nM) and in vivo, without the classical agonism. |
|
| DC11607 |
JTZ-951(Enarodustat)
Featured
|
A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2. |
|
| DC11608 |
JTZ-951 hydrochloride |
A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2. |
|
| DC11985 |
PSTC |
A novel potent, selective Nrf2 activator with pEC50 of 7.7 (inducing of NQO1 specific enzyme activity). |
|
| DC11547 |
LY-2562175
Featured
|
LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM. |
|
| DC11822 |
YD-277 |
A novel small molecule KLF5 inhibitor derived from ML264, demonstrates >10-fold enhanced efficacy in multiple cancer cell lines with IC50 of 1.5-10 uM. |
|
| DC11908 |
Ralaniten |
A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer. |
|
| DC11909 |
Ralaniten acetate |
A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer. |
|
| DC11786 |
THPN
Featured
|
A potent nuclear receptor TR3 (Nur77)-specific targeting compound that can induce melanoma autophagy through a mitochondrial signaling pathway. |
|
| DC11794 |
GNF-351
Featured
|
GNF-351 is a potent, pure aryl hydrocarbon receptor (AHR) antagonist (IC50=62 nM) devoid of partial agonist potential; antagonizes agonist and SAhRM-mediated suppression of SAA1, inhibit both DRE-dependent and -independent activity; decreases migration and invasion of HNSCC cells and prevents benzo[a]pyrene-mediated induction of the chemotherapy efflux protein ABCG2. |
|
| DC11870 |
RORγt-IN-9a |
A potent, selective, CNS penetrant, orally bioavailable RORγt with pIC50 of 8.3 in FRET assays. |
|
| DC11621 |
eIF4A3-IN-1q |
A potent, subtype-selective, orally available eIF4A3 inhibitor with IC50 of 0.14 uM. |
|
| DC7054 |
AM580
Featured
|
A retinoic acid analog and selective RARα agonist |
|
| DC11918 |
CMLD010509 |
A rocaglate (flavagline) derivative that acts a highly specific inhibitor of the oncogenic translation program supporting MM, including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. |
|
